Biogen (BIIB) Tops Q2 EPS by $1.12; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Biogen's (BIIB) "P&L Remains Challenged", Focus on CLARITY-AD - BMO Maintains Stock at Market Perform
July 20, 2022 7:53 AM EDTBMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $217.00 price target on Biogen (NASDAQ: BIIB), following the company's most recent quarterly report.
The analyst comments: "Good enough quarter with a top- and bottom-line beat, but all that really... More
